89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Pegozafermin's Promise | Explore 89bio's lead candidate in Phase III trials for MASH and SHTG, potentially unlocking billion-dollar market opportunities in liver and cardio-metabolic diseases |
Market Dynamics | Delve into the evolving landscape of MASH treatments, including the impact of GLP-1 therapies and how pegozafermin aims to differentiate itself |
Financial Outlook | Analyst targets range from $12 to $49 per share, reflecting varied assumptions about pegozafermin's potential across multiple indications |
Strategic Positioning | Learn how 89bio's pipeline-in-a-product strategy and favorable regulatory environment could shape its future in the competitive biopharmaceutical space |
Metrics to compare | ETNB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETNBPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.9x | −2.8x | −0.7x | |
PEG Ratio | 0.07 | 0.06 | 0.00 | |
Price/Book | 4.2x | 3.0x | 2.6x | |
Price / LTM Sales | - | 42.6x | 3.4x | |
Upside (Analyst Target) | 68.9% | 158.6% | 38.0% | |
Fair Value Upside | Unlock | −1.3% | 5.3% | Unlock |